Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Aprea Therapeutics Q3 EPS $(0.64) Beats $(0.72) Estimate, Sales $354.62M Beat $225.00K Estimate

Author: Benzinga Newsdesk | November 07, 2024 08:08am
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.72) by 11.11 percent. This is a 25.58 percent increase over losses of $(0.86) per share from the same period last year. The company reported quarterly sales of $354.62 million which beat the analyst consensus estimate of $225.00 thousand by 157.51K percent. This is a 110.90K percent increase over sales of $319.47 thousand the same period last year.

Posted In: APRE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist